Literature DB >> 22037893

Validation of a common data model for active safety surveillance research.

J Marc Overhage1, Patrick B Ryan, Christian G Reich, Abraham G Hartzema, Paul E Stang.   

Abstract

OBJECTIVE: Systematic analysis of observational medical databases for active safety surveillance is hindered by the variation in data models and coding systems. Data analysts often find robust clinical data models difficult to understand and ill suited to support their analytic approaches. Further, some models do not facilitate the computations required for systematic analysis across many interventions and outcomes for large datasets. Translating the data from these idiosyncratic data models to a common data model (CDM) could facilitate both the analysts' understanding and the suitability for large-scale systematic analysis. In addition to facilitating analysis, a suitable CDM has to faithfully represent the source observational database. Before beginning to use the Observational Medical Outcomes Partnership (OMOP) CDM and a related dictionary of standardized terminologies for a study of large-scale systematic active safety surveillance, the authors validated the model's suitability for this use by example. VALIDATION BY EXAMPLE: To validate the OMOP CDM, the model was instantiated into a relational database, data from 10 different observational healthcare databases were loaded into separate instances, a comprehensive array of analytic methods that operate on the data model was created, and these methods were executed against the databases to measure performance.
CONCLUSION: There was acceptable representation of the data from 10 observational databases in the OMOP CDM using the standardized terminologies selected, and a range of analytic methods was developed and executed with sufficient performance to be useful for active safety surveillance.

Entities:  

Mesh:

Year:  2011        PMID: 22037893      PMCID: PMC3240764          DOI: 10.1136/amiajnl-2011-000376

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  7 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  A comparison of observational studies and randomized, controlled trials.

Authors:  K Benson; A J Hartz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

3.  Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.

Authors:  Paul E Stang; Patrick B Ryan; Judith A Racoosin; J Marc Overhage; Abraham G Hartzema; Christian Reich; Emily Welebob; Thomas Scarnecchia; Janet Woodcock
Journal:  Ann Intern Med       Date:  2010-11-02       Impact factor: 25.391

4.  Guidelines for the effective use of entity-attribute-value modeling for biomedical databases.

Authors:  Valentin Dinu; Prakash Nadkarni
Journal:  Int J Med Inform       Date:  2006-11-13       Impact factor: 4.046

5.  The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials.

Authors:  R Kunz; A D Oxman
Journal:  BMJ       Date:  1998-10-31

Review 6.  Measuring effects without randomized trials? Options, problems, challenges.

Authors:  L E Moses
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

7.  Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.

Authors:  Stephanie J Reisinger; Patrick B Ryan; Donald J O'Hara; Gregory E Powell; Jeffery L Painter; Edward N Pattishall; Jonathan A Morris
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

  7 in total
  173 in total

1.  An Interoperable Similarity-based Cohort Identification Method Using the OMOP Common Data Model version 5.0.

Authors:  Shreya Chakrabarti; Anando Sen; Vojtech Huser; Gregory W Hruby; Alexander Rusanov; David J Albers; Chunhua Weng
Journal:  J Healthc Inform Res       Date:  2017-06-08

2.  Hypothesis-Free Search for Connections between Birth Month and Disease Prevalence in Large, Geographically Varied Cohorts.

Authors:  John P Borsi
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

3.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.

Authors:  S V Wang; P Verpillat; J A Rassen; A Patrick; E M Garry; D B Bartels
Journal:  Clin Pharmacol Ther       Date:  2016-03       Impact factor: 6.875

4.  Trends in biomedical informatics: automated topic analysis of JAMIA articles.

Authors:  Dong Han; Shuang Wang; Chao Jiang; Xiaoqian Jiang; Hyeon-Eui Kim; Jimeng Sun; Lucila Ohno-Machado
Journal:  J Am Med Inform Assoc       Date:  2015-11       Impact factor: 4.497

5.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

6.  Electronic health records-driven phenotyping: challenges, recent advances, and perspectives.

Authors:  Jyotishman Pathak; Abel N Kho; Joshua C Denny
Journal:  J Am Med Inform Assoc       Date:  2013-12       Impact factor: 4.497

7.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

8.  Managing data quality for a drug safety surveillance system.

Authors:  Abraham G Hartzema; Christian G Reich; Patrick B Ryan; Paul E Stang; David Madigan; Emily Welebob; J Marc Overhage
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

9.  An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.

Authors:  Xiaofeng Zhou; Sundaresan Murugesan; Harshvinder Bhullar; Qing Liu; Bing Cai; Chuck Wentworth; Andrew Bate
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

10.  Signalling paediatric side effects using an ensemble of simple study designs.

Authors:  Jenna M Reps; Jonathan M Garibaldi; Uwe Aickelin; Daniele Soria; Jack E Gibson; Richard B Hubbard
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.